Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma

Cancer Research

Volumn 71, Issue 3, 2011, Pages 1041-1049

  Paillas, Salomé ^a   Boissière, Florence ^b   Bibeau, Fréderic ^b   Denouel, Amélie ^b   Mollevi, Caroline ^b   Causse, Annick ^a   Denis, Vincent ^a   Vezzio Vié, Nadia ^a   Marzi, Laetitia ^a   Cortijo, Cédric ^a   Ait Arsa, Imade ^a   Askari, Nadav ^c   Pourquier, Philippe ^a   Martineau, Pierre ^a   Del Rio, Maguy ^a   Gongora, Céline ^a  

^a INSERM   (France)

^b CENTRE VAL D AURELLE   (France)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; FLUOROURACIL; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE P38; OXALIPLATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; FLUOROURACIL; HCT116 CELLS; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; ISOENZYMES; LEUCOVORIN; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79551559585     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2726     Document Type: Article

References (40)

1. Segal NH, Saltz LB. Evolving treatment of advanced colon cancer. Ann Rev Med 2009;60:207-19.
2. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5.
3. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006;6:789-802.
4. Xu Y, Villalona-Calero MA. Irinotecan:mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 2002;13:1841-51. (Pubitemid 36040772)
5. Candeil L, Gourdier I, Peyron D, Vezzio N, Copois V, Bibeau F, et al. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. Int J Cancer 2004;109:848-54.
6. van Ark-Otte J, Kedde MA, van Der Vijgh WJF, Dingemans A-MC, Jansen WJM, Pinedo HM, et al. Determinants of CPT-11 and SN-38 activities in human lung cancer cells. Br J Cancer 1998;77:2171-6.
7. Tan KB, Mattern MR, Eng WK, McCabe FL, Johnson RK. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 1989;81:1732-5.
8. Saleem A, Edwards TK, Rasheed Z, Rubin EH. Mechanisms of resistance to camptothecins. Ann N Y Acad Sci 2000;922:46-55.
9. Sugimoto Y, Tsukahara S, Oh-hara T, Isoe T, Tsuruo T. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res 1990;50:6925-30.
10. Husain I, Mohler JL, Seigler HF, Besterman JM. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 1994;54:539-46.
11. Park SY, Lam W, Cheng YC. X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance. Cancer Res 2002;62:459-65.
12. Pommier Y, Redon C, Rao VA, Seiler JA, Sordet O, Takemura H, et al. Repair of and checkpoint response to topoisomerase I-mediated DNA damage. Mutat Res 2003;532:173-203.
13. Gongora C, Candeil L, Vezzio N, Copois V, Denis V, Breil C, et al. Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38. Cancer Biol Ther 2008;7:822-32.
14. Zarubin T, Han J. Activation and signaling of the p38 MAP kinase pathway. Cell Res 2005;15:11-18. (Pubitemid 41653958)
15. Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 2007;1773:1358-75.
16. Wilson KP, Fitzgibbon MJ, Caron PR, Griffith JP, Chen W, McCaffrey PJ, et al. Crystal structure of p38 mitogen-activated protein kinase. J Biol Chem 1996;271:27696-700.
17. Ventura JJ, Tenbaum S, Perdiguero E, Huth M, Guerra C, Barbacid M, et al. p38alpha MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat Genet 2007;39:750-8.
18. Robinson VL, Hickson JA, Vander Griend DJ, Dubauskas Z, Rinker-Schaeffer CW. MKK4 and metastasis suppression:a marriage of signal transduction and metastasis research. Clin Exp Metastasis 2003;20:25-30.
19. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009;9:537-49.
20. Chiacchiera F, Simone C. Signal-dependent regulation of gene expression as a target for cancer treatment: inhibiting p38alpha in colorectal tumors. Cancer Lett 2008;265:16-26.
21. Vié N, Copois V, Bascoul-Mollevi C, Denis V, Bec N, Robert B, et al. Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells. Mol Cancer 2008;7:14.
22. Avitzour M, Diskin R, Raboy B, Askari N, Engelberg D, Livnah O. Intrinsically active variants of all human p38 isoforms. FEBS J 2007;274:963-75. (Pubitemid 46204416)
23. Subramanian D, Kraut E, Staubus A, Young DC, Muller MT. Analysis of topoisomerase I/DNA complexes in patients administered topotecan. Cancer Res 1995;55:2097-103.
24. Granci V, Bibeau F, Kramar A, Boissière-Michot F, Thézénas S, Thirion A, et al. Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas. Eur J Cancer 2008;44:2312-318.
25. Del Rio M, Molina F, Bascoul-Mollevi C, Copois V, Bibeau F, Chalbos P, et al. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol 2007;25:773-80.
26. Wood CD, Thornton TM, Sabio G, Davis RA, Rincon M. Nuclear localization of p38 MAPK in response to DNA damage. Int J Biol Sci 2009;5:428-37.
27. Woessner RD, Eng WK, Hofmann GA, Rieman DJ, McCabe FL, Hertzberg RP, et al. Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. Oncol Res 1992;4:481-8.
28. Wang XS, Diener K, Manthey CL, Wang S, Rosenzweig B, Bray J, et al. Molecular cloning and characterization of a novel p38 mitogen-activated protein kinase. J Biol Chem 1997;272:23668-74.
29. Arakawa Y, Suzuki H, Saito S, Yamada H. Novel missense mutation of the DNA topoisomerase I gene in SN-38-resistant DLD-1 cells. Mol Cancer Ther 2006;5:502-8.
30. Van Der Merwe M, Bjornsti MA. Mutation of Gly721 alters DNA topoisomerase I active site architecture and sensitivity to camptothecin. J Biol Chem 2008;283:3305-15.
31. Losasso C, Cretaio E, Fiorani P, D'Annessa I, Chillemi G, Benedetti P. A single mutation in the 729 residue modulates human DNA topoisomerase IB DNA binding and drug resistance. Nucleic Acids Res 2008;36:5635-44.
32. Chiacchiera F, Matrone A, Ferrari E, Ingravallo G, Lo Sasso G, Murzilli S, et al. p38alpha blockade inhibits colorectal cancer growth in vivo by inducing a switch from HIF1alpha- to FoxO-dependent transcription. Cell Death Differ 2009;16:1203-14.
33. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 2007;11:175-89.
34. Comes F, Matrone A, Lastella P, Nico B, Susca FC, Bagnulo R, et al. A novel cell type-specific role of p38alpha in the control of autophagy and cell death in colorectal cancer cells. Cell Death Differ 2007;14:693-702.
35. Zhao HY, Ooyama A, Yamamoto M, Ikeda R, Haraguchi M, Tabata S, et al. Molecular basis for the induction of an angiogenesis inhibitor, thrombospondin-1, by 5-fluorouracil. Cancer Res 2008;68:7035-41.
36. Chiu SJ, Chao JI, Lee YJ, Hsu TS. Regulation of gamma-H2AX and securin contribute to apoptosis by oxaliplatin via a p38 mitogen-activated protein kinase-dependent pathway in human colorectal cancer cells. Toxicol Lett 2008;179:63-70.
37. Ling X, He X, Apontes P, Cao F, Azrak RG, Li F. Enhancing effectiveness of the MDR-sensitive compound T138067 using advanced treatment with negative modulators of the drug-resistant protein surviving. Am J Transl Res 2009;1:393-405.
38. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 2005;23:2469-76.
39. Owens DM, Keyse S. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 2007;26:3203-13.
40. Wen J, Feng Y, Huang W, Chen H, Liao B, Rice L, et al. Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. Leuk Res 2010;34:85-92.